Newsletter · · Ashutosh Agarwal

Lilly Buys a Second Act as the FDA Clears a Fourth Breast Cancer Drug - Weekly Pharma / Biotech / Life Sciences Podcast Recap - Week of August 30, 2026

Weekly Pharma / Biotech / Life Sciences Podcast Recap for the week of August 23 to 30, 2026. Podcast synthesis on Eli Lilly settling an old Zyprexa case while spending $3.8 billion on vaccine companies and raising guidance, Curium's roughly $8 billion takeout of Lantheus days after an FDA imaging approval, and oncologists debating gedatolisib against capivasertib after the FDA cleared a fourth drug in the PI3K pathway.

Weekly Pharma / Biotech / Life Sciences Podcast Recap

Week of August 30, 2026: Lilly Buys a Second Act as the FDA Clears a Fourth Breast Cancer Drug

Window: Aug 23 to Aug 30, 2026.

Two episodes carried the week, and both are worth knowing something about before you weigh what they said. The first is Telltales, a weekly markets recap that is an AI-generated program, synthetic hosts narrating the week's real corporate events, so treat its opinions as automated commentary and its facts as the verifiable corporate record they are drawn from. The second is Oncology Today with Dr. Neil Love, a continuing-medical-education discussion between two breast-cancer specialists, which means clinical judgment rather than a stock call. What surfaced through them was genuinely meaningful: one FDA drug approval that remakes a whole treatment category, a takeover of a nuclear-imaging company, and a busy week for Eli Lilly.

1. Dominant themes

Theme 1: a busy, four-sided week for Eli Lilly (LLY), with a legal settlement, a spending spree, and a guidance raise, all in seven days. The Telltales recap put it well: for Lilly, "one of those four things led the coverage, and only one of those is going to be visible a few years out." What happened, in the show's telling:

  • Lilly agreed to plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act and pay roughly $800 million to settle an old case about how it promoted the antipsychotic Zyprexa. The show's point: this is the past being cleaned up, not the future. Against Lilly's roughly $21 billion of trailing free cash flow (the cash a company generates after running the business and investing in it), $800 million is, in the hosts' words, "about two weeks of production."
  • In the same seven days, Lilly announced deals to buy three vaccine and infectious-disease companies for $3.8 billion, and put $50 million up front into a cancer-vaccine (mRNA) partnership with CureVac worth up to $1.8 billion. The hosts flagged these as the ones "I'd actually underwrite, because that's Lilly buying a second act while GLP-1 is still paying for everything," in other words using the enormous cash flow from its obesity and diabetes franchise to build a new growth engine in vaccines.
  • Lilly also raised full-year revenue guidance to $85 to $87 billion.

Source: Telltales, "Weekend Update - W2634" (Aug 23, 2026).

Theme 2: radiopharmaceuticals keep drawing buyers, with Curium taking out Lantheus (LNTH) days after an FDA approval. Telltales reported that Curium agreed to acquire all of Lantheus for $102.50 a share in cash, plus contingent value rights (extra payments tied to future milestones) worth up to $12 more, a total potential value around $8 billion, with the deal expected to close in the first half of 2027. The timing is the tell: the agreement landed five days after the FDA approved TauClarify, Lantheus's tau-PET imaging agent used to spot the tau protein tangles involved in Alzheimer's disease in adults being evaluated for the condition. Lantheus pulled its own full-year guidance when the deal was signed, which, as the hosts noted, "is what a company does when the forecast stops being its decision."

An investing detail worth catching for anyone who follows merger situations: Lantheus was still trading below the $102.50 cash price. That gap exists because of the long regulatory road to a 2027 close, "what a long regulatory close does to an arbitrage spread," as the show put it. Source: Telltales.

Theme 3: a new class of breast-cancer drugs is crowding in fast, and the FDA just approved a fourth one. The Oncology Today discussion centered on drugs that block the PI3K / AKT / mTOR pathway, a chain of signals inside cells that hormone-driven breast cancers use to keep growing after standard hormone therapy stops working. Roughly 40 percent of hormone-receptor-positive breast cancers carry an activating PIK3CA mutation, which is what makes this pathway such a big commercial target. Dr. Hope Rugo of City of Hope walked through how the field went from "we had two or three agents approved and that was it" a few years ago to "six agents with several more on clinical trials" today. The single biggest news: the FDA approved gedatolisib (heavily garbled in the auto-transcript as "getitolisib" and "get-a-tolasib") the day before the recording. More on that specific drug and company below. Source: Oncology Today with Dr Neil Love, "HR-Positive Metastatic Breast Cancer, Year in Review" (Aug 23, 2026).

2. Active debates

Both shows this week were more descriptive than argumentative, but a few genuine two-sided questions came through.

Debate 1: for Eli Lilly, which of this week's four events actually matters? The Telltales hosts came down clearly: ignore the $800 million legal settlement (closed, small, backward-looking) and the guidance raise (expected), and focus on the vaccine and infectious-disease acquisitions as the thing that will "be visible a few years out." The bear angle they implied but did not press: Lilly is buying its way into a category "it doesn't have," so execution and integration risk is real. The debate they left open is whether a GLP-1 giant can build a credible second franchise by acquisition.

Debate 2: is legal risk or growth risk the bigger danger to a stock? This was a broader point the hosts made using Meta and Lilly as bookends, and it is a useful frame for pharma investors sitting on litigation overhangs: "Lilly's legal exposure is closed and quantified... Meta's is open and unquantified." Their read was that markets often mis-rank these two, and that sometimes an open, unquantified legal cloud is scarier than the eventual dollar number.

Debate 3 (clinical, with direct stock consequences): in post-hormone-therapy breast cancer, which mechanism wins, oral pills or an IV drug? The oncologists debated gedatolisib (IV, given three weeks out of four) versus capivasertib (oral). The efficiency case for the IV drug is compliance, "it's IV, so you know patients are getting it" (Dr. Virginia Kaklamani). The case against is convenience and a specific side effect (mouth sores, below). Their verdict leaned toward the newcomer: "based on this data, it seems that the efficacy is pretty favorable for [gedatolisib]." For investors, that clinician preference is exactly the kind of real-world adoption signal that decides whether a newly approved drug actually takes market share.

Debate 4: oral SERD versus PI3K-pathway drug for the double-mutant patient. About 20 percent of these patients carry both an ESR1 and a PIK3CA mutation, and there is a genuine clinical toss-up over what to give them. Dr. Kaklamani's practical rule: for milder, still-hormone-sensitive disease, use a single oral SERD (a hormone pill) because "it's so much better tolerated"; for a bigger tumor burden, reach for capivasertib. Both approaches are landing "a median progression-free survival of around five and a half months" in that group, a reminder that the incremental benefit is still modest, which matters when weighing the premium valuations some of these drugmakers carry.

3. Stock by stock: what was said, and what it means

A caveat: neither show is a stock-picking podcast. Telltales gives short as-priced valuation takes on the companies it covers; Oncology Today is a clinical discussion that never mentions tickers. Where a drug maps to a specific company, that mapping is added as background so the clinical signal is usable, but the bull and bear framing is drawn from what the shows actually said plus the plain read-through, not from a guest making a formal stock call.

Eli Lilly (LLY). Bull, as framed: using GLP-1 cash to buy a genuine second act in vaccines and infectious disease ($3.8B of deals) plus a CureVac cancer-vaccine option; raised full-year revenue to $85 to $87 billion; the $800M Zyprexa settlement is trivial against about $21B of free cash flow. Bear, as framed: the stock is expensive, with Telltales carrying it at 58 times trailing free cash flow, and Lilly is buying into a category it does not currently operate, so the new franchise is a bet, not a sure thing. Source: Telltales.

Lantheus (LNTH). Bull: it got a buyer, Curium at $102.50 a share in cash plus up to $12 in milestone payments (about $8B total), on the back of a fresh FDA approval (TauClarify for Alzheimer's imaging), at a clean balance sheet ("essentially no debt"). The show noted Curium is paying about 15 times trailing free cash flow for a company that traded around 12 times, a real premium. Bear and risk: the deal does not close until the first half of 2027, and the shares trade below the cash price, so anyone buying the spread is locking up money for a long, regulator-dependent wait. Source: Telltales.

Harrow (HROW), the one name Telltales said it actually owns. Bull: "it just put up the quarter the thesis needed," with Q2 revenue of $71 million, up 60 percent sequentially and 11 percent year over year, and the dry-eye drug VEVYE contributing $29 million; management reiterated full-year guidance of $350 to $365 million in revenue and $80 to $100 million of adjusted EBITDA; and new prospective randomized data showed its product IHEZO delivered about 58 percent less patient-reported discomfort following injections into the eye. Bear: the balance sheet is stretched, with the show flagging 10.5 times leverage on free cash flow, adding that "60% sequential growth on a balance sheet that tight is a good problem, right up until it's the only problem." Source: Telltales.

Celcuity (CELC), the marquee catalyst of the week. The FDA approval the oncologists spent much of the episode on is for gedatolisib, and gedatolisib is Celcuity's lead (and effectively only) product; the pivotal study they kept referencing, VIKTORIA-1, is Celcuity's trial. Per the closing note read into the episode, the FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for HR-positive/HER2-negative advanced or metastatic breast cancer without a PIK3CA mutation, after progression on at least one prior line of hormone therapy, based on Study 1 of VIKTORIA-1. Why the clinicians were excited: it is a dual PI3K plus mTOR inhibitor, meaning it hits two points on the pathway at once, so it works in both mutated and wild-type (non-mutated) tumors. Efficacy signals they cited: a response rate of "almost 80%" with a median progression-free survival of "48.4 months" in an earlier treatment-naïve group, and in the pivotal setting, PFS of roughly 9 and 7 months versus about 2 months for fulvestrant alone. Both the two-drug and three-drug regimens were approved. For a company whose entire value rests on this asset, a broad label covering the large non-mutated population is about as good an outcome as the setup allowed. The read-through risk is delivery and tolerability (below) and the fact that a sub-cutaneous, easier-to-give formulation is still in development. Source: Oncology Today with Dr Neil Love.

AstraZeneca (AZN), capivasertib (brand name Truqap). The oncologists reviewed CAPItello-291 overall-survival data (presented at ESMO Breast) and made a nuanced point investors should note: the trial was only "50% powered to detect an overall survival benefit in the mutant population," so the lack of a clean survival win is partly a trial-design artifact rather than proof the drug does not extend life, "it doesn't negate the benefits of capivacertib." They also noted a numeric survival edge in the roughly 70 percent of patients who had had prior CDK4/6 inhibitors, and that capivasertib is now also approved in prostate cancer (in patients with PTEN deficiency). Practical takeaway: capivasertib stays a workhorse second-line oral option, but gedatolisib is now a real competitor for the same patients. Source: Oncology Today with Dr Neil Love.

Roche / Genentech (RHHBY), inavolisib (brand name Itovebi). In the INAVO120 trial the drug delivered "a six- to seven-month improvement in overall survival, not just progression-free survival" in first-line, endocrine-resistant patients with a PIK3CA mutation, a meaningfully strong result, since overall-survival wins are harder to achieve than delaying progression. The follow-on INAVO123 trial (in more hormone-sensitive patients) is ongoing and would expand the eligible population if positive. Source: Oncology Today with Dr Neil Love.

Novartis (NVS), alpelisib (Piqray) and everolimus (Afinitor). These are the older drugs in the class. Alpelisib was repeatedly described as the toxicity benchmark to beat, with "hyperglycemia, rash, diarrhea," and all-grade high blood sugar around 58 percent. Everolimus is a repurposed older mTOR inhibitor. The clear direction of travel is newer, better-tolerated drugs taking share from these, a modest negative read-through for the incumbents in this specific indication. Source: Oncology Today with Dr Neil Love.

On the radar: next-generation mutant-selective PI3K-alpha drugs. The doctors flagged two Phase 3 assets they are excited about (names badly mangled by the transcription, so treat spellings as approximate): one tested in the PICOLO2 trial that they identified as an Eli Lilly drug, and another being tested head-to-head against capivasertib in the REDISCOVER trial. The appeal is much lower rates of the class's signature side effects, "both have low [hyperglycemia]... we don't see a lot of rash, and we don't see a lot of diarrhea." These are the next competitive wave in this category, still a year or more from decisions. Source: Oncology Today with Dr Neil Love.

Flagged but not detailed this week: Moderna (MRNA), Merck (MRK), BioNTech (BNTX). Telltales said its mid-week episode (2635, airing Wednesday Aug 27) would spend "more than half the show" on Moderna's Phase III melanoma readout with Merck and a capital-allocation scoreboard against BioNTech. That episode falls outside this window, so there is no substance to report yet, but it is the one to watch next. Source: Telltales.

4. Notable quotes

Lilly bought its way out of the past and into a category it doesn't have in the same week, and only one of those is going to be visible a few years out. The vaccine and infectious disease deals are the ones I'd actually underwrite, because that's Lilly buying a second act while GLP-1 is still paying for everything.

Telltales, "Weekend Update - W2634" (Aug 23, 2026)

Bought and re-rated inside one week, and Lantheus pulled its own full year guidance when the agreement was signed, which is what a company does when the forecast stops being its decision.

Telltales, on the Curium and Lantheus takeover (Aug 23, 2026)

60% sequential growth on a balance sheet that tight is a good problem, right up until it's the only problem.

Telltales, on Harrow (Aug 23, 2026)

We had two or three agents approved and that was it. And now we have six agents with several more on clinical trials that will likely lead to approval.

Dr. Virginia Kaklamani, Oncology Today with Dr Neil Love (Aug 23, 2026), on how crowded the post-hormone-therapy breast-cancer market has become

It's IV, so you know patients are getting it. So compliance is much easier with an IV agent than it is with an oral agent... based on this data, it seems that the efficacy is pretty favorable for [gedatolisib].

Dr. Virginia Kaklamani, Oncology Today with Dr Neil Love (Aug 23, 2026), on the newly approved drug's real-world edge

The rate of grade three stomatitis [mouth sores] was 19% in the triplet arm... and 12% with the doublet.

Dr. Hope Rugo, Oncology Today with Dr Neil Love (Aug 23, 2026), on the main tolerability hurdle for gedatolisib

5. Catalysts to watch

  • Gedatolisib and Celcuity (CELC) launch execution. The label is broad (it covers the large non-PIK3CA-mutated population), but adoption hinges on managing mouth sores and on the IV versus oral choice. Watch for the sub-cutaneous formulation, which clinicians repeatedly called "critical," and for early prescribing signals. (Oncology Today)
  • Curium and Lantheus (LNTH) deal close, first half of 2027. A long regulatory runway; the shares trade below the $102.50 cash price, so the merger spread is the thing to monitor, along with any competing bid or antitrust wrinkle. (Telltales)
  • Eli Lilly (LLY) vaccine and infectious-disease integration. Three acquisitions ($3.8B) plus the CureVac mRNA-cancer option ($50M upfront, up to $1.8B). Watch for deal specifics, closings, and pipeline detail on the second act. (Telltales)
  • Moderna (MRNA) plus Merck (MRK) Phase III melanoma readout. Flagged by Telltales for its mid-week episode. (Telltales)
  • Ongoing breast-cancer Phase 3 trials, including VIKTORIA-2 (gedatolisib, first-line), CAPItello-292 (capivasertib triplet), INAVO123 (inavolisib, endocrine-sensitive), PICOLO2 and REDISCOVER (next-gen mutant-selective PI3K-alpha drugs), and the ELEVATE trial (elacestrant plus capivasertib). These define who takes share next. (Oncology Today)